A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Study Details
Study Description
Brief Summary
This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18 weeks for participants with DLBCL and 24 weeks for participants with FL.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Arm A (Phase II Randomization): Polatuzumab+BR in FL Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Active Comparator: Arm B (Phase II Randomization): BR in FL Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Active Comparator: Arm D (Phase II Randomization): BR in DLBCL Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Arm E (Phase II Expansion): Polatuzumab+BG in FL Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Obinutuzumab
Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Obinutuzumab
Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Obinutuzumab
Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Obinutuzumab
Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Liquid)
Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
|
Experimental: Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Lyophilized)
Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
Other Names:
|
Experimental: Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL. |
Drug: Bendamustine
Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Rituximab
Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
Other Names:
Drug: Polatuzumab vedotin (Lyophilized)
Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Phase Ib: Percentage of Participants with Adverse Events [From Baseline until up to 90 days after last dose (up to 36 weeks overall)]
- Phase II: Percentage of Participants with Complete Response (CR) According to Modified Lugano Criteria as Measured by Positron Emission Tomography (PET)/Computed Tomography (CT) Scan and Determined by Independent Review Committee (IRC) [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Pharmacokinetics: Area Under Concentration-Time Curve (AUC) of Polatuzumab (lyophilized) in Arm G [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: Maximum Concentration (Cmax) of Polatuzumab (lyophilized) in Arm G [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: Systemic Clearance (CL) of Polatuzumab (lyophilized) in Arm G [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: Steady-State Volume of Distribution (Vss) of Polatuzumab (lyophilized) in Arm G [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; randomly during post-treatment period (up to 2 years overall)
- Arm G (Phase II NF Cohort): Percentage of Participants with Adverse Events [From Baseline up to 2 years]
- Arm H (Phase II NF Cohort): CR Rate According to Modified Lugano Criteria as Measured by PET-CT at the Time of Primary Response Assessment and Determined by IRC [6-8 weeks after Cycle 6, Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
Secondary Outcome Measures
- Percentage of Participants with CR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Percentage of Participants with CR or Partial Response (PR) According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by IRC and Investigator [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Percentage of Participants with CR According to Modified Lugano Criteria as Measured by CT Scan and Determined by IRC and Investigator [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by CT Scan and Determined by IRC and Investigator [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Percentage of Participants by Best Objective Response (BOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan only and Determined by the Investigator [Baseline, Cycle 3 Day 15, 6-8 weeks after Cycle 6 Day 1 (cycle length: 21 or 28 days), then every 6 months until progression, withdrawal or study close (up to about 4.5 years overall)]
- Phase II: Percentage of Participants with Adverse Events [From Baseline until up to 90 days after last dose (up to 36 weeks overall)]
- Phase Ib: Percentage of Participants with Anti-Drug Antibodies (ADAs) to Polatuzumab in Cohort 1A [Pre-dose (0 to 4 hours [h]) on Day 2 of Cycle 1; pre-dose (0 to 4 h) on Day 1 of Cycles 2 and 4; randomly during post-treatment period (up to 2 years overall)]
- Phase Ib: Percentage of Participants with ADAs to Polatuzumab and Obinutuzumab in Cohort 1B [Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; pre-dose (0 to 4 h) on Day 2 of Cycle 1; randomly during post-treatment period (up to 2 years overall)]
- Phase II: Percentage of Participants with ADAs to Polatuzumab in Arms A and C [Pre-dose (0 to 4 h) on Day 1 of Cycles 2, 4; pre-dose (0 to 4 h) on Day 2 of Cycle 1; up to 30 days after last dose (approximately 28 weeks); randomly during post-treatment period (up to 2 years overall)]
- Phase II: Percentage of Participants with ADAs to Polatuzumab and Obinutuzumab in Arms E and F [Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; pre-dose (0 to 4 h) on Day 2 of Cycle 1; up to 30 days after last dose (approximately 28 weeks); randomly during post-treatment period (up to 2 years overall)]
- Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Rituximab in Cohort 1A (milligrams per milliliter [mg/mL]) [Predose (0 to 4 h), end of infusion (EOI) (Duration of infusion: 90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2, Cycle 1 and Day 1 of Cycles 2,4; Days 8,15 of Cycle 1; randomly during post-treatment period (up to 2 years overall)]
- Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Obinutuzumab in Cohort 1B (mg/mL) [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycle 1, 2, 4 and Day 2 of Cycle 1; on Days 8, 15 of Cycle 1; at EOI (Duration of infusion: 90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 2, 4; randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Rituximab in Cohort 1A (hour * milligrams per milliliter [h*mg/mL]) [Pre-dose (0 to 4 h) and EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 2, 4; on Days 8, 15 of Cycle 1; randomly during post-treatment period (up to 2 years overall)]
- Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Obinutuzumab in Cohort 1B (h*mg/mL) [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycle 1, 2, 4 and Day 2 of Cycle 1; on Days 8, 15 of Cycle 1; at EOI (Duration of infusion: 90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 2, 4; randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Rituximab in Arms A and C (mg/mL) [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; at EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Rituximab in Arms A and C (h*mg/mL) [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4; at EOI (Duration of infusion: 90 minutes for first infusion and 30 minutes for subsequent infusions) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: Cmax of Bendamustine and Rituximab in Arms B and D (mg/mL) [Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Days 1, 2 of Cycle 1; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1 (up to 3 months overall)]
- Pharmacokinetics: AUC of Bendamustine and Rituximab in Arms B and D (h*mg/mL) [Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion:90 minutes [1st infusion], 30 minutes [subsequent infusions]) on Days 1, 2 of Cycle 1; post-dose (1, 2, 3, 4 h) on Day 2 of Cycle 1 (up to 3 months overall)]
- Pharmacokinetics: Cmax of Polatuzumab, Bendamustine, and Obinutuzumab in Arms E and F (mg/mL) [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion: 90 minutes for first infusion and 30 minutes for subsequent infusions) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)
- Pharmacokinetics: AUC of Polatuzumab, Bendamustine, and Obinutuzumab in Arms E and F (h*mg/mL) [Day 1 up to 2 years (detailed timeframe is given in outcome description section)]
Detailed timeframe: Pre-dose (0 to 4 h) on Day 1 of Cycles 1, 2, 4 and Day 2 of Cycle 1; at EOI (Duration of infusion: 90 minutes for first infusion and 30 minutes for subsequent infusions) on Day 2 of Cycle 1 and Day 1 of Cycles 1, 4; post-dose (1, 2, 3, 4 h) Day 2 of Cycle 1; after last dose (24 weeks); randomly during post-treatment period (up to 2 years overall)
- Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F [Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)]
- Phase II NF Cohort: Duration of Response (DOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan and Determined by the Investigator and IRC [From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to about 4.5 years overall)]
- Phase II NF Cohort: Progression Free Survival (PFS) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan and Determined by the Investigator and IRC [From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to about 4.5 years overall)]
- Phase II NF Cohort: Percentage of Participants with CR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Phase II NF Cohort: Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by the Investigator and IRC [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Phase II NF Cohort (Arm G): Percentage of Participants with CR According to Modified Lugano Criteria as Measured by CT Scan only and Determined by the Investigator and IRC [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Phase II NF Cohort (Arm G): Percentage of Participants with CR or PR According to Modified Lugano Criteria as Measured by CT Scan only and Determined by the Investigator and IRC [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
- Phase II NF Cohorts: Percentage of Participants by BOR According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan only and Determined by the Investigator and IRC [Baseline, Cycle 3 Day 15, 6-8 weeks after Cycle 6 Day 1 (cycle length: 21 or 28 days), then every 6 months until progression, withdrawal or study close (up to about 4.5 years overall)]
- Phase II NF Cohorts: Percentage of Participants with ADAs to Polatuzumab (lyophilized) in Arms G and H [Pre-dose Cycle 1 Day 2, Cycle 2 Day 1, Cycle 4 Day 1; 30 days after last infusion Cycle 6 Day 1; randomly during post-treatment period (up to 2 years overall)]
- Phase II NF Cohorts: Event-Free Survival (EFS) Based on PET-CT or CT only, as Determined by the Investigator [Up to 50 months]
- Phase II NF Cohorts: Overall Survival (OS) [Up to 50 months]
- Pharmacokinetics: Area Under Concentration-Time Curve (AUC) of Polatuzumab (lyophilized) in Arm H [Day 1 up to 1 year (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; during follow up at Month 3
- Pharmacokinetics: Maximum Concentration (Cmax) of Polatuzumab (lyophilized) in Arm H [Day 1 up to 1 year (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; during follow up at Month 3
- Pharmacokinetics: Systemic Clearance (CL) of Polatuzumab (lyophilized) in Arm H [Day 1 up to 1 year (detailed timeframe is given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; during follow up at Month 3
- Pharmacokinetics: Steady-State Volume of Distribution (Vss) of Polatuzumab (lyophilized) in Arm H [Day 1 up to 1 year (detailed timeframe given in outcome description section)]
Detailed time frame: Pre and post-dose on Cycle 1 Day 2, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1; 6 days after Day 2 infusion Cycle 1 Day 8; 13 days after Day 2 infusion Cycle 1 Day 15; 7 days after Day 2 infusion Cycle 3 Day 8; 14 days after Day 2 infusion Cycle 3 Day 15; 30 days after last infusion Cycle 6 Day 1; during follow-up at Month 3
- DLBCL Cohorts: Percentage of Participants by Best Objective Response (BOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan Only and Determined by IRC [Baseline, Cycle 3 Day 15, 6-8 weeks after Cycle 6 Day 1 (cycle length: 21 or 28 days), then every 6 months until progression, withdrawal or study close (up to about 4.5 years overall)]
- DLBCL Cohorts: Duration of Response (DOR) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan and Determined by IRC [From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to about 4.5 years overall)]
- DLBCL Cohorts: Progression Free Survival (PFS) According to Modified Lugano Criteria as Measured by PET/CT Scan or CT Scan and Determined by IRC [From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to about 4.5 years overall)]
- Phase II NF Cohort (Arm G): Percentage of Participants with CR According to Modified Lugano Criteria as Measured by PET/CT Scan and Determined by IRC [6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 or 28 days) or last dose of study drug (up to 28 weeks overall)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histologically confirmed relapsed or refractory FL (Grades 1, 2, or 3a) or relapsed or refractory DLBCL
-
If the participant has received prior bendamustine, response duration must have been greater than (>) 1 year (for participants who have relapse disease after a prior regimen)
-
At least one bi-dimensionally measurable lesion on imaging scan defined as >1.5 centimeters (cm) in its longest dimension
-
Confirmed availability of archival or freshly collected tumor tissue
-
The Phase II NF Cohorts (Arms G and H) will be required to submit tissue and pathology report for central pathology review.
-
Life expectancy of at least 24 weeks
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
-
Adequate hematological function unless inadequate function is due to underlying disease
Exclusion Criteria:
-
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine products
-
Contraindication to bendamustine, rituximab, or obinutuzumab
-
Prior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4 weeks or 5 half-lives before Cycle 1 Day 1
-
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to Cycle 1 Day 1
-
Ongoing corticosteroid use >30 mg per day prednisone or equivalent, for purposes other than lymphoma symptom control
-
Completion of autologous stem cell transplant (SCT) within 100 days prior to Cycle 1 Day 1
-
Prior allogeneic SCT
-
Eligibility for autologous SCT
-
Grade 3b FL
-
History of transformation of indolent disease to DLBCL
-
Primary or secondary CNS lymphoma
-
Current Grade >1 peripheral neuropathy
-
Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results, including significant cardiovascular disease (such as New York Heart Association Class III or IV cardiac disease, myocardial infarction within the last 6 months, unstable arrhythmias, or unstable angina) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
-
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization within 4 weeks prior to Cycle 1 Day 1
-
Suspected or latent tuberculosis
-
Positive test results for chronic hepatitis B virus (HBV) infection or for hepatitis C virus (HCV) antibody
-
Known history of human immunodeficiency virus (HIV) seropositive status or known infection with human T-cell leukemia virus 1 (HTLV-1) virus
-
Women who are pregnant or lactating or who intend to become pregnant within a year of the last dose of study treatment in the rituximab cohort or within 18 months of last dose in the obinutuzumab cohort
-
Evidence of laboratory abnormalities in standard renal, hepatic, or coagulation function tests
-
Treatment with chimeric antigen receptor T-cell therapy within 100 days prior to Cycle 1, Day 1
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Alabama at Birmingham | Birmingham | Alabama | United States | 35294-3300 |
2 | Clearview Cancer Institute | Huntsville | Alabama | United States | 35805 |
3 | City of Hope National Medical Center | Duarte | California | United States | 91010 |
4 | Univ of Colorado Canc Ctr | Aurora | Colorado | United States | 80045 |
5 | Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy) | Jacksonville | Florida | United States | 32256 |
6 | Emory Univ Winship Cancer Inst | Atlanta | Georgia | United States | 30322 |
7 | Joliet Oncology-Hematology; Associates, Ltd. | Joliet | Illinois | United States | 60435 |
8 | Horizon Oncology Research, Inc. | Lafayette | Indiana | United States | 47905 |
9 | Weinberg CA Inst Franklin Sq | Baltimore | Maryland | United States | 21237 |
10 | Regional Cancer Care Associates LLC - Morristown | Morristown | New Jersey | United States | 07962 |
11 | University of New Mexico Cancer Center | Albuquerque | New Mexico | United States | 87131 |
12 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
13 | Levine Cancer Institute | Charlotte | North Carolina | United States | 28204 |
14 | West Clinic | Germantown | Tennessee | United States | 38138 |
15 | Swedish Cancer Inst. | Seattle | Washington | United States | 98104 |
16 | Northwest Medical Specialties | Tacoma | Washington | United States | 98405 |
17 | Prince of Wales Hospital; Oncology | Randwick | New South Wales | Australia | 2031 |
18 | Royal Adelaide Hospital | Adelaide | South Australia | Australia | 5000 |
19 | Adelaide Cancer Centre | Kurralta Park | South Australia | Australia | 5037 |
20 | Monash Medical Centre; Haematology Research | Clayton | Victoria | Australia | 3168 |
21 | BCCA-Vancouver Cancer Centre | Vancouver | British Columbia | Canada | V5Z 4E6 |
22 | Queen Elizabeth II Health Sciences Centre; Oncology | Halifax | Nova Scotia | Canada | B3H 2Y9 |
23 | Hopital Maisonneuve- Rosemont; Oncology | Montreal | Quebec | Canada | H1T 2M4 |
24 | Jewish General Hospital | Montreal | Quebec | Canada | H3T 1E2 |
25 | Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika | Brno | Czechia | 625 00 | |
26 | Fakultni nemocnice Hradec Kralove | Hradec Kralove | Czechia | 500 05 | |
27 | Fakultní nemocnice Ostrava Klinika hematoonkologie | Ostrava | Czechia | 70852 | |
28 | I Interni klinika; Vseobecna fakultni nemocnice | Prague 2 | Czechia | 128 08 | |
29 | Chu Site Du Bocage;Hematologie Clinique | Dijon | France | 21079 | |
30 | Centre Hospitalier Departemental Les Oudairies | La Roche Sur Yon | France | 85925 | |
31 | Centre Leon Berard; Departement Oncologie Medicale | Lyon | France | 69373 | |
32 | CHU Saint Eloi; Service d'Hématologie Clinique | Montpellier | France | 34295 | |
33 | CHU Lyon Sud - Service Hématologie | Pierre Benite | France | 69310 | |
34 | Centre Henri Becquerel; Hematologie | Rouen | France | 76038 | |
35 | HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie | Erfurt | Germany | 99089 | |
36 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Abt. für Hämatologie und Onkologie | Mainz | Germany | 55131 | |
37 | Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Hämatologie, Onkologie und Pallia. | Minden | Germany | 32429 | |
38 | Gemeinschaftspraxis für Hämatologie und Onkologie | Münster | Germany | 48153 | |
39 | Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale | Regensburg | Germany | 93053 | |
40 | Semmelweis University, First Dept of Medicine | Budapest | Hungary | 1083 | |
41 | National Institute of Oncology, A Dept of Internal Medicine | Budapest | Hungary | 1122 | |
42 | University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B | Debrecen | Hungary | 4032 | |
43 | Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica | Napoli | Campania | Italy | 80131 |
44 | A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia | Brescia | Lombardia | Italy | 25123 |
45 | Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia | Milano | Lombardia | Italy | 20141 |
46 | Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia | Alessandria | Piemonte | Italy | 15121 |
47 | Seoul National University Hospital | Seoul | Korea, Republic of | 03080 | |
48 | Samsung Medical Center | Seoul | Korea, Republic of | 06351 | |
49 | UMC St. Radboud; Hematology | Nijmegen | Netherlands | 6525 GA | |
50 | Hospital Universitari Vall d'Hebron; Servicio de Hematologia | Barcelona | Spain | 08035 | |
51 | Hospital Clinic i Provincial de Barcelona; Hematology | Barcelona | Spain | 08036 | |
52 | Hospital Universitario la Paz; Servicio de Hematologia | Madrid | Spain | 28046 | |
53 | Hospital Clinico Universitario de Salamanca;Servicio de Hematologia | Salamanca | Spain | 37007 | |
54 | Hospital Universitario Virgen del Rocio; Servicio de Hematologia | Sevilla | Spain | 41013 | |
55 | Ankara University; Hematology | Ankara | Turkey | 06620 | |
56 | Dokuz Eylul Uni ; Hematology | Izmir | Turkey | 35100 | |
57 | Ondokuzmayis University Medical Faculty Heamatology Department | Samsun | Turkey | 55139 | |
58 | Karadeniz Technical Uni School of Medicine; Hematology | Trabzon | Turkey | 61800 | |
59 | KING'S COLLEGE HOSPITAL; Commercial R&D Amendments, King's Health Partner's Clinical Trials Office | London | United Kingdom | SE1 9RT | |
60 | Christie Hospital Nhs Trust; Medical Oncology | Manchester | United Kingdom | M2O 4BX | |
61 | Nottingham City Hospital; Dept of Haematology | Nottingham | United Kingdom | NG5 1PB | |
62 | Southampton General Hospital; Somers Cancer Research Building | Southampton | United Kingdom | SO16 6YD |
Sponsors and Collaborators
- Hoffmann-La Roche
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GO29365
- 2014-001361-28